



SOP: Approving apheresis and high risk immune effector cell trials

Organisation: The Christie NHS Foundation Trust

Document version number: 2

Date written: 11/11/20

End user rights:

This document is shared with permission for re-use to distribute, remix, adapt, and build upon the material in any medium or format for non-commercial purposes only, so long as the attributions listed below are given.

Attributions: The Christie NHS Foundation Trust

This document is made available under a Creative Commons Attribution-NonCommercial 4.0 International License as described here:

https://creativecommons.org/licenses/by-nc/4.0/

The information, materials and any opinions contained in this document are provided for general information and educational purposes only, are not intended to constitute legal, medical or other professional advice and should not be relied on or treated as a substitute for specific advice relevant to particular circumstances. Although we make all reasonable efforts to ensure the information is up to date, we make no representations, warranties or guarantees in that regard. In no event shall the creator(s) be liable for any direct, indirect, special, consequential or other claims, losses or damages that are related to the use or reliance whatsoever in the content of the document or any part thereof, except to the extent that such liability cannot be excluded by law. We do not seek to exclude or limit in any way our liability to the user for personal injury or death caused as a result of our negligence or seek to exclude or limit our liability for fraud or fraudulent misrepresentation by us.

Funded by









We reserve the right to make changes and improvements to any information contained within this document, at any time and without notice. Where this document contains hyperlinks to other websites operated by parties not connected to us, such hyperlinks are provided for your reference only. We do not control such websites and are not responsible for their contents. The inclusion of hyperlinks from this document or the website to such websites does not imply any endorsement of the material on such websites or any association with their operators. We accept no responsibility of any nature whatsoever for linked web sites or any information contained in them.

Funded by







TITLE: APPROVING APHERESIS AND HIGH RISK IMMUNE EFFECTOR CELL TRIALS

Code:	QM-11	Issue No:	02	No. of Pages:	05	Copy No:	00
Replaces: V1		Revision details	: Minor	formatting an	d pers	sonnel upda	ates
Author		Simon Cliffo					

Author	Simon Cliffe	
Programme Director	Adrian Bloor	
Clinical Services Manager	Jo Tomlins	

1.0 INDICATIONS OF PRACTICE

As part of the process to achieve capacity and capability confirmation from the Christie Research Division for a clinical trial, the Cellular Therapy and Transplant Programme must internally approve relevant aspects of each trial involving apheresis and/or high risk immune effector cell therapy. Ensuring any differences between the trial protocol and Programme SOPs and policies are highlighted and discussed to ascertain whether the trial can be facilitated.

This SOP aims to ensure that proposed trial protocols requiring access to the Cellular Therapy and Transplant Programme services are reviewed by the appropriate staff prior to being authorised to open.

2.0 AUTHORISED PERSONNEL/TRAINING REQUIRED

Programme Director/Clinical Services Manager are responsible and accountable for ensuring the procedures for clinical trials are in line with JACIE approved policies or deviations against the programme are approved prior to the trial being approved. They must also attend or send a designee to the monthly Cellular Therapy Operational (CTO) meeting to approve or reject proposed trials using the programmes services. The Clinical Services Manager is also responsible for the financial sign off of the programme relevant aspects of the trial for the Palatine Ward.

Collection Facility Medical Director is responsible for having oversight and approving all trials using the technical aspects of the collection facility in accordance with the JACIE standards. They must attend the monthly CTO meetings when trials using the collection facility are presented for approval.

Do not remove from SOP folder. Do not photocopy				
Effective date:	11/11/2020	Review:	2 years	
QM-11	Vers	sion 2	Page 1 of 5	



TITLE: APPROVING APHERESIS AND HIGH RISK IMMUNE EFFECTOR CELL TRIALS

Study Delivery Team is responsible for ensuring all the appropriate trial relating procedural documentation is reviewed and approved by all relevant staff prior to the trial opening.

Apheresis staff/Stem Cell Lab staff/Palatine and CRF Clinical Practice Facilitators are responsible for reviewing the trial procedures relevant to their role and assessing the capacity and capability of the trial, highlighting any areas that do not comply with current standard practice as defined by programme SOPs and policies. A representative must attend the monthly CTO Meeting to present the findings and relay these to the appropriate trial team.

Haematology Quality Manager is responsible for ensuring the trial procedure documentation is reviewed by the appropriate staff prior to the study opening. Secondly helping to present the findings of the reviewed trials at the monthly CTO Meeting and feeding back to trial teams.

It is also the responsibility of the quality manager to keep a record/spreadsheet of the trials (appendix 7.1).

3.0 PROCEDURE

- 3.1 Once the trial sponsor has provided the trial specific procedure manual/s (e.g. Investigator Brochure, Apheresis Manual, Lab Manual, Cell Handling Manual, Final Product Manual etc.) these must be forwarded to the appropriate staff for review by the Study Delivery Team:
- Any procedural documents relating to Apheresis must be sent to the Lead Nurse for Apheresis.
- Any procedural documents relating to the Stem Cell Lab must be sent to the Stem Cell Laboratory Manager.
- Any procedural documents relating to the Palatine Ward (e.g. infusion of cells) must be sent to the Palatine Ward Senior Clinical Practice Facilitator.
- Any procedural documents relating to the Clinical Research Facility (CRF) (e.g. infusion of cells) must be sent to the CRF Senior Clinical Practice Facilitator.
- Costings sheet/financial agreement to be sent to the Haematology Clinical Services Manager.

The procedural manuals will be reviewed to ascertain any differences between the trial protocol and standard practice as defined by Programme SOPs and policies.



TITLE: APPROVING APHERESIS AND HIGH RISK IMMUNE EFFECTOR CELL TRIALS

3.2 Once the review of the trial procedural documents has taken place the trials are presented at the monthly CTO meeting. Within this meeting an overview of the trial and any discrepancies between the protocol and programme SOPs and policies are presented and discussed. A decision will be minuted as to whether the trial protocol can be facilitated or whether there are further discussions required with the trial team and sponsor. If there is urgency in obtaining trial approval the trial can be approved outside the meeting and noted at the next CTO meeting.

If the clinical trial involves different processes than the standard programme procedures the trial must be reviewed at the CTO meeting and one of the following options will be agreed;

- 1. Programme SOPs should be changed in line with the trial procedures or;
- 2. It is acceptable for the programme to deviate from standard practices or;
- 3. The procedures within the trial are unsafe/impracticable and therefore the trial cannot be approved unless the trial sponsor agrees to alter the protocol in line with the programme procedures.

In the event of the second option being agreed the procedures will need to be documented in the delineation of responsibilities document that will be written for each trial/trial specific crib sheet. All staff involved in the new procedures must receive the relevant training.

Once all staff groups are satisfied with the trial procedures and that the programme has the capacity to deliver the trial the Programme Director and clinical services manager can authorise for those sections of the trial to be approved. This will be fed back to the trial team by the Quality Manager. Escalation of issues if a solution is not found is done in the monthly Quality Management Meeting (QMM).

If option three is agreed and the trial cannot be supported this will be fed back to the research team, Research ATMP committee and ATMP Board with justification as to why the study can't be supported.

3.3 Once the relevant cellular therapy and transplant programme services are approved the trial team with input from the relevant service team (e.g. apheresis, stem cell lab, ward/CRF staff etc.) must complete and upload to Q-Pulse a delineation of responsibilities (AGR-1) prior to the study opening for recruitment. The apheresis team will also complete a trial specific crib sheet which clearly defines the procedures required; these will be stored in the apheresis room in Department 26.



TITLE: APPROVING APHERESIS AND HIGH RISK IMMUNE EFFECTOR CELL TRIALS

The Clinical Services Manager will send financial approval to the Study Delivery Team for the programme relevant aspects of the trial.

4.0 FLOWCHART

Apheresis and high risk immune effector cell trial presented at the monthly ATMP feasibility meeting.

Study Delivery Team provides the apheresis and cell handling manuals from the trial sponsor.

Quality Manager distributes the manuals to the Lead Nurse for Apheresis, Clinical Practice Facilitator and Stem Cell Laboratory Manager for review at least one week prior to CTO meeting.

The trial is presented at the monthly CTO meeting for discussion from the relevant teams (e.g. Apheresis, stem cell lab, clinical practice facilitator) around the requirements of the study and whether the facilities have the capacity and capability to deliver the trial as per trial protocol.

Trial approval status agreed in the CTO meeting. Approval status will be minuted.

Once the trial has been approved the Quality Manager will inform the relevant trials team and update the trial database.

The trial team with input from the apheresis and stem cell lab teams will complete a delineation of responsibilities (AGR-1) form and upload this to Q-Pulse.



TITLE: APPROVING APHERESIS AND HIGH RISK IMMUNE EFFECTOR CELL TRIALS

5.0 FURTHER INFORMATION/EXCEPTIONS

Cellular Therapy and Transplant Programme Director: Adrian Bloor - adrian.bloor@christie.nhs.uk

Clinical Services Manager: Jo Tomlins - jo.tomlins@christie.nhs.uk

Stem Cell Laboratory Manager: Diane Sweeney - diane.sweeney@christienhs.uk

Lead Nurse for Apheresis: Rita Angelica - rita.angelica@christie.nhs.uk

Palatine Ward Clinical Practice Facilitator: Ruth Clout
RuthElizabeth.Clout@christie.nhs.uk

Clinical Research Facility Clinical Practice Facilitator: Laura McNab Laura.McNab@christie.nhs.uk

6.0 REFERENCES

The Christie Research Division process for capacity and capability is defined in:

- R&D 001.000 Research Study Set Up Capacity and Capability Process
- R&D 001.002 Capacity and Capability Assessment

7.0 APPENDICES

7.1 Appendix 1 - Spreadsheet



Do not remove from SOP folder. Do not photocopy				
Effective date:	11/11/2020	Review:	2 years	